imal Experimentation Committee of St. Marianna University.
Cells SH-SY5Y human neuroblastoma cells (American Type Culture Collection, Rockville, MD, U.S.A.) were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, U.S.A.)/Ham's F-12 medium (Invitrogen) containing 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic (Invitrogen).
Drugs Am-80 (4[(5,6,7,8-tetrahydro-5,5,8,8 ,-tetramethyl-2-naphthalenyl)carbamoyl] benzoic acid) was kindly provided by R & R Co., Ltd. (Tokyo, Japan). All-trans retinoic acid (ATRA) was purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.).
Spinal Cord Injury and Drug Treatment Impact injury of the spinal cord was induced by using the weight-drop device developed at New York University (NYU impact model), according to the method described by Takenaga et al. 26, 27) and Kitagawa et al. 28) Adult female SD rats weighing 210-230 g were anesthetized and dorsal laminectomy was performed at the T 10 level, after which a 10 g weight was dropped onto the spinal cord from a height of 25 mm.
Motor function was assessed by using the Basso Beattie Bresnahan (BBB) 29, 30) open field locomotor scale. Animals were allowed to walk around freely in a circular field (1.2 m in diameter) for 10 min while movements of the hindlimbs were closely observed. The BBB locomotor scale includes frequency and quality of hindlimb movement as well as forelimb/hindlimb coordination. From these observations, the animal received a score between 0 and 21 such that 0 indicated total absence of movement and 21 indicated normal movement. Two researchers were trained as observers to evaluate the animals on the BBB scale. All observers were unaware of the group identity of the animals. Rating of each animal was later checked by video recordings of walking observed at slow playback speed. Scores for the left and right extremities were averaged. A Treadmill ® (Muromachi Co., Ltd., Tokyo) was also employed for evaluation of motor function.
Drug treatment was carried out as follows. Oral group: Am-80 (3 mg/kg) suspended in 0.5% carboxymethylcellulose (CMC) was administered orally at 1 h before injury, followed by once daily until day 21. Subcutaneous (s.c.) group: Am-80 (0.15 mg/kg) was administered via the s.c. route immediately after injury, followed by once daily treatment until day 21. SCI control group: The vehicle (0.5% CMC at 1 ml/kg) was given orally according to the same protocol as in the oral group. The doses of Am-80 were selected on the basis of data reported by Mizojiri et al., 31) who showed that oral dosing of 3 mg/kg to rats was almost equivalent to subcutaneous one of 0.15 mg/kg.
Staining of Spinal Cord Specimens
On day 28 after injury (after observation of motor function), animals were perfused with cold saline and then with 4% paraformaldehyde in phosphate-buffered saline by intracardiac injection under anesthesia, after which the part of the spinal cord containing the damaged region (1.5 cm length) was removed. Spinal cord specimens were embedded in paraffin and were cut into 8 mm for Kluver-Barrera (KB) staining. The area of the cavity in each section was quantified by WinROOF ® software (Mitani Co., Tokyo).
For immunohistochemical staining, 4 mm sections were prepared. It was performed with primary antibodies for glial fibrillary acidic protein (GFAP, mouse; Sigma-Aldrich), brainderived neurotrophic factor (BDNF, rabbit; Chemicon International), tyrosine kinase B (TrkB) (rabbit; Santa Cruz Biotechnology), and nestin (mouse; Chemicon International). Rhodamine-conjugated anti-mouse immunoglobulin G (IgG) (Rockland, Gilbertsville, PA, U.S.A.), fluorescein isothiocyanate (FITC) -conjugated anti-rabbit IgG (Chemicon International), and FITC-conjugated anti-mouse IgG (Sigma-Aldrich) were used as the secondary antibodies. Fluorescent images were acquired by employing conventional microscope equipped with CCD camera (model IX70, Olympus, Melville, NY, U.S.A.). Before mounting, the sections were counterstained with Hoechst33352 (Dojindo, Kumamoto).
Western Blot Analysis On day 28 after injury, animals were perfused with cold saline by intracardiac injection under anesthesia, and the part of the spinal cord containing the damaged area (1.5 cm length) was removed.
Aliquots of spinal cord lysate (20 mg) in 20 mM Tris-HCl, pH 7.5, 1% Triton-X100, 150 mM NaCl, 5 mM EDTA, 1 mM PMSF, 5 mg/ml aprotinin were subjected to electrophoresis on 5-20% gradient SDS polyacrylamide gels. The protein concentration was determined by using a BCA protein assay kit (Pierce, IL, U.S.A.). Proteins were transferred to PVDF membranes (Clearblot P TM , ATTO Corporation, Tokyo) and were incubated with anti-myelin binding protein (MBP) goat IgG (Santa Cruz Biotechnology), anti-bIIItubulin mouse IgG (Promega, Madison, WI, U.S.A.), anti-GFAP mouse IgG, anti-TrkB rabbit IgG, or anti-b-actin mouse IgG (Sigma-Aldrich). Then the membranes were incubated with ECL horseradish peroxidase (HRP)-labeled anti-goat IgG (Santa Cruz Biotechnology), HRP-labeled anti-mouse IgG, or HRPlabeled anti-rabbit IgG (Amersham Biosciences, Backinghamshire, U.K.). Finally, each membrane was incubated with ECL plus TM Western blotting detection reagents (Amersham Biosciences), and was exposed to Polaroid film. Immunoblot signals were quantified with a densitometer.
In Vitro Study Using SH-SY5Y Cells SH-SY5Y human neuroblastoma cells were cultured in the presence or absence of Am-80 or ATRA. Differentiation was induced by culture with Am-80 or ATRA (10 mM) for 5 d. Drugs were subsequently removed by changing the medium, and a further 7 d of incubation with 100 ng/ml of BDNF (Regeneron Pharmaceuticals Inc., NY, U.S.A.) was carried out in medium without FBS.
Then the MTT assay and a [ 3 H]thymidine (methyl, 1Ј,2Ј-3 H thymidine; 1.40 TBq/mmol, Amersham) incorporation study were carried out. Western blot analysis of the cell lysate (20 mg) was performed as described above with anti-TrkB rabbit IgG, anti-neurofilament (NF)-M IgG (Biomol International, LP) or anti-b-actin mouse IgG.
The real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was performed by using total RNA extracted with TRIzol ® reagent (Invitrogen). After reverse transcription of 1 mg of total RNA, an aliquot of the cDNA thus obtained was amplified with a LightCycler system (Roche, Penzberg, Germany) using LightCycler FastStart DNA Master SYBR Green I (Roche) according to the manufacturer's instructions. The sequences of the primers employed were as follows:
bIIItubulin (forward: 5Ј-GCGAGATGTACGAAGACGA-C-3Ј; reverse: 5Ј-TTTAGACACTGCTGGCTTCG-3Ј, 115 bp), TrkB (forward: 5Ј-CCTAACCTCACTGTGGAGGAA-3Ј; re-verse: 5Ј-ATCTGCTTCCCACTGTCATCG-3Ј, 182 bp), and hypoxanthine phosphoribosyltransferase (HPRT) (forward: 5Ј-GACCAGTCAACAGGGGACAT-3Ј; reverse: 5Ј-AACA-CTTCGTGGGGTCCTTTTC-3Ј, 195 bp; internal control).
Statistical Analysis Statistical analysis was performed by using the Mann-Whitney U-test or the Student's t-test, and pϽ0.05 was taken to indicate significance.
RESULTS

Hindlimb Motor Function after Am-80 Treatment of SCI Rats
Am-80 promoted the recovery of hindlimb motor dysfunction induced by SCI ( Fig. 1 ). On day 6 after injury, the BBB functional score was 4.29Ϯ2.9 (meanϮS.D.) in the oral group and 1.29Ϯ1.3 in the SCI control group (pϽ0.05). The subcutaneous group (s.c. group) also showed significant improvement of the BBB score to 3.75Ϯ1.9 (pϽ0.05 vs. SCI control). On day 15, the BBB score was 11.1Ϯ2.8 in the oral group and 7.92Ϯ1.9 in the SCI control group. The s.c. group also showed a marked improvement of the BBB score to 10.6Ϯ1.9 and a significant difference from the SCI control group was observed.
Animals with a BBB score of more than 10 at 3 weeks after injury could take Treadmill ® test (Table 1) , including 3 out of 7 SCI controls, 5 out of 7 from the oral group, and 5 out of 8 from the s.c. group. When the test was carried out at the speed of 8 m/min for 5 min, the SCI control and oral Am-80 groups walked on 4 legs for 2 min 39 s and 2 min 57 s, respectively, while the s.c. group walked for 3 min 52 s. The mean frequency of touching the wall because of not walking was 48.3 for controls, 16 .0 for the oral group, and 13.4 for the s.c. group. There was a significant difference between Am-80-treated animals and SCI controls. Treatment with Am-80 improved functional recovery and the mean BBB score was 11.4 in the oral group (nϭ7) and 12.7 in the s.c. group (nϭ8) versus 9.14 in the SCI control group (nϭ7).
Lesion Cavity Next, we focused on the day 28 spinal cord specimens. Figure 2a shows the result of Kluver-Barrera (KB) staining. The lesion area decreased in the ventral direction and the cavity volume of the oral and s.c. groups was 66.7Ϯ15.4% and 50.4Ϯ14.9%, respectively, when the volume of the SCI control group was considered to be 100% (Fig. 2b) .
Neural Marker Expression Luxol fast blue stain ( Fig.  2a ) clearly revealed axonal myelin in the spinal cord. SCI reduced the myelin content (myelin binding protein; MBP) as shown in Fig. 3a . The expression of MBP was significantly restored after Am-80 treatment (for oral 2.6-fold and 3.1-fold for s.c. than in SCI controls).
After SCI, the expression of bIIItubulin (marker of neuron) decreased, but it was significantly restored (2 to 3-fold increase) by Am-80 treatment (Fig. 3b ). SCI also reduced the expression of GFAP (marker of astrocyte) compared with that in the normal spinal cord. When quantified by Western blot analysis, a 2.5-fold increase was found after Am-80 treatment compared with the SCI control group (Fig. 3c ).
Spinal cord lysate was also used for the detection of TrkB (receptor of neurotrophic factor including BDNF). SCI induced the marked reduction of TrkB expression compared with that in the normal spinal cord. However, a 3.6-3.8 times increase was observed in Am-80-treated spinal cord compared with the SCI control group (Fig. 3d) .
Immunohistochemical staining revealed that numerous GFAP-positive cells were found around the spinal cord lesions (Fig. 4a ). BDNF-positive cells also showed an increase around the lesion as GFAP-positive ones (Fig. 4b ). Around the site of injury, TrkB-positive ( Fig. 4c ) and nestin (marker of neural progenitor/stem cell)-positive cells (Fig. 4d ) were observed.
In Vitro Effects of Am-80 As demonstrated by Encinas et al., 25) ATRA induced neuronal differentiation by SH-SY5Y cells when combined with BDNF. Exposure to ATRA (10 mM) followed by addition of BDNF (100 ng/ml), promoted extensive neurite outgrowth (Fig. 5a ). Not only morphological changes, but also an increase of TrkB and neurofilament (NF)-M (mature neuron) was observed ( Fig. 5b) . Expression of the bIIItubulin and TrkB genes was increased Data are expressed as the meanϮS.E. intensity relative to that of the SCI control group, which was set at 1.0. nϭ3-4, * pϽ0.05, and * * pϽ0.01 vs. SCI control. N: normal spinal cord lysate. by 1.2-and 100-fold above the control level, respectively (Fig. 5c ).
Am-80 also promoted a marked increase in the expression of both bIIItubulin and NF-M along with neurite outgrowth (Figs. 5a, b ). It should be noted that TrkB gene expression was increased by 250-fold over the control level (Fig. 5c ).
Cell cycle arrest after addition of ATRA has been reported. 24) Although not shown, Am-80 (as well as ATRA) dose-dependently suppressed thymidine incorporation with little effect on cell viability up to the dose of 10 mM. It should be noted that exposure to Am-80 followed by addition of BDNF, significantly inhibited thymidine incorporation compared with the effect of ATRA (Fig. 5d ).
DISCUSSION
This study showed that Am-80, a synthetic retinoid, could significantly improve hindlimb motor dysfunction induced by SCI in rats. Evaluation with the BBB score revealed that Am-80 significantly promoted functional recovery compared to that seen in the SCI control rats during the early phase (days 5, 6) as well as the late phase. The Treadmill ® test performed at 3 weeks after injury also demonstrated that Am-80-treated SCI animals were able to walk for longer while maintaining forelimb-hindlimb coordination and integrated motor movements. Both oral (3 mg/kg) and subcutaneous (0.15 mg/kg) treatment with Am-80 achieved a significant improvement, but the latter was more effective. Am-80 is a low-molecular compound (MW351) and is lipo-philic. Therefore, even after treated via oral route, Am-80 would have been distributed to the injured spinal cord, and have retained for longer.
The lesion cavity in the spinal cord was significantly smaller in treated animals, indicating that Am-80 might have prevented cell death and/or promoted regeneration. Expression of every marker quantified by Western blot analysis was reduced in SCI rats compared with animals having an intact spinal cord, and these markers were significantly increased by treatment with Am-80. These results might reflect the decrease of lesion cavity. In particular, a decrease of MBP indicates demyelination, which is a crucial factor in SCI. 32, 33) The increase of MBP expression suggests that Am-80 promoted axonal regrowth (remyelination) and/or prevented cell death. A lot of GFAP-positive cells were observed around the lesion site. Okada et al. have reported that activated astrocytes not only have an inhibitory function but also are involved in regeneration. 34) Therefore, that might suggest that an increase of activated astrocytes (increased GFAP) contributed partly to the improvement of functional recovery. In fact, some of GFAP-positive cells seemed to be BDNF-positive (Fig. 4 ). This indicates that activated astrocyte might produce BDNF. It should be noted that TrkB (145 kDa; tyrosine kinase activity), the receptor of neurotrophic factors including BDNF, showed more expression in Am-80-treated spinal cord compared to SCI controls, although the level was much lower than in the normal spinal cord.
Retinoids are expected to promote the recovery of SCIinduced motor dysfunction. Mey et al. 21) reported that SCI induced retinoic acid (RA) production over time with a peak of from 7 to 14 d after injury, indicating that the response to spinal cord damage involves RA. Wyatt et al. 35) and Arrieta et al. 36) have proposed that RA binds to its receptors to stimulate neurotrophic factor production and differentiation of stem cells into mature neurons, astrocytes, and oligodendrocytes to reform the neural network, thus leading to an improvement of performance. In fact, Am-80-treated spinal cord had a lot of nestin-positive cells around the injury site, indicating that Am-80 might promote neuronal differentiation from neural stem cells.
SH-SY5Y cells were used in order to prove the hypothesis, since Giannini et al. 24) demonstrated that treatment of SH-SY5Y cells with RA (all trans-RA; ATRA) led to reduced proliferation and an increase of neurite outgrowth. Pahlman et al. 37) showed that removal of ATRA after 5 d of incubation, followed by addition of BDNF in serum-free medium, induced a more neuronal phenotype along with a marked extensive increase of neuron-specific markers and TrkB expression. We confirmed these observations, as shown in Fig. 5 . It should be noted that Am-80 treatment augmented TrkB gene expression until it was over twice as high as with ATRA. In addition, significant suppression of thymidine uptake was observed. These findings suggest that augmented TrkB expression around the damaged region of the spinal cord promoted endogenous BDNF synthesis and sustained cell viability and neuronal differentiation from stem cells in Am-80 treated rats.
Injury has been reported to lead to the translocations of RARa and retinoid receptors into the cell nucleus. 22) Zechel 38) has demonstrated an RARa agonist induces neuronal differentiation along with increased RARa expression. Corcoran et al. 39) found that RARb plays an important role in neurite outgrowth. Wong et al. 40) showed that transfection of the RARb gene promoted axonal regeneration across the dorsal root entry zone and achieved recovery in the performance of various tasks. Therefore, the selective stimulation of RARa/b by Am-80 apparently had a beneficial effect on motor function in SCI rats. The significant reduction of thymidine incorporation might also indicate an increase of neuronal differentiation due to the superior effect of Am-80 as RARa/b agonist, but further in vivo comparison with ATRA is required to confirm this hypothesis.
The present study demonstrated that Am-80, a synthetic selective RARa/b agonist, significantly improved hindlimb motor dysfunction induced by SCI in rats. The mechanisms involved may be prevention of cell death and promotion of the differentiation of neural stem cells through augmented TrkB expression. Am-80 is a stable retinoid and is used in clinical, so it may be a better choice for the treatment of SCI.
Promotion of neuronal differentiation by another retinoid derivative has already been reported, 41) as well as by other selective agonists. 24, 38) Cell replacement therapy is currently attracting attention as a potentially attractive strategy for the treatment of neurodegenerative diseases including SCI. Am-80 combined with cell therapy 42) might provide a new strategy for SCI.
